{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:09:43Z","timestamp":1789189783347,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":61,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_824","type":"book-chapter","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:53:04Z","timestamp":1789188784000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals"],"prefix":"10.1007","author":[{"given":"Ele","family":"Ferrannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"824_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2337\/db19-0770","volume":"69","author":"M Alatrac","year":"2020","unstructured":"Alatrac M et al (2020) Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors. Diabetes 69:681\u2013688. https:\/\/doi.org\/10.2337\/db19-0770","journal-title":"Diabetes"},{"key":"824_CR2","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.2337\/dc24-2244","volume":"48","author":"EM Apperloo","year":"2025","unstructured":"Apperloo EM et al (2025) Exploring kidney oxygenation responses to dapagliflozin, exenatide, and their combination in patients with type 2 diabetes and chronic kidney disease: observations from a prespecified pilot study of a randomized crossover trial. Diabetes Care 48:e22\u2013e24. https:\/\/doi.org\/10.2337\/dc24-2244","journal-title":"Diabetes Care"},{"key":"824_CR3","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1210\/clinem\/dgad088","volume":"108","author":"E Biancalana","year":"2023","unstructured":"Biancalana E et al (2023) Empagliflozin and renal sodium-hydrogen exchange in healthy subjects. J Clin Endocrinol Metab 108:e567\u2013e573","journal-title":"J Clin Endocrinol Metab"},{"key":"824_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106554","volume":"142","author":"C Borghi","year":"2025","unstructured":"Borghi C et al (2025) Crystal clear - part I: the role of uric acid in cardiorenal disease. Eur J Intern Med 142:106554. https:\/\/doi.org\/10.1016\/j.ejim.2025.106554","journal-title":"Eur J Intern Med"},{"key":"824_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00042.2012","volume":"95","author":"M Carlstr\u00f6m","year":"2015","unstructured":"Carlstr\u00f6m M et al (2015) Renal autoregulation in health and disease. Physiol Rev 95:405\u2013511","journal-title":"Physiol Rev"},{"key":"824_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.101328","volume":"10","author":"AA Challa","year":"2025","unstructured":"Challa AA et al (2025) Ketone bodies in cardiovascular disease. The vasculature as a therapeutic target. JACC Basic Transl Sci 10:101328. https:\/\/doi.org\/10.1016\/j.jacbts.2025.101328","journal-title":"JACC Basic Transl Sci"},{"key":"824_CR7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","volume":"86","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86:1057\u20131058","journal-title":"Kidney Int"},{"key":"824_CR8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y et al (2014) SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35:391\u2013404","journal-title":"Biopharm Drug Dispos"},{"key":"824_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1681\/ASN.2015111282","volume":"28","author":"MJ Coady","year":"2016","unstructured":"Coady MJ et al (2016) MAP17 is a necessary activator of renal Na+\/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85\u201393. https:\/\/doi.org\/10.1681\/ASN.2015111282","journal-title":"J Am Soc Nephrol"},{"key":"824_CR10","doi-asserted-by":"publisher","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","volume":"304","author":"DG Cotter","year":"2013","unstructured":"Cotter DG et al (2013) Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 304:H1060\u2013H1076. https:\/\/doi.org\/10.1152\/ajpheart.00646.2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"824_CR11","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA et al (2013) Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36:3169\u20133176. https:\/\/doi.org\/10.2337\/dc13-0387","journal-title":"Diabetes Care"},{"key":"824_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA et al (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13:11\u201326","journal-title":"Nat Rev Nephrol"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","volume":"17","author":"RA DeFronzo","year":"2021","unstructured":"DeFronzo RA et al (2021) Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 17:319\u2013334. https:\/\/doi.org\/10.1038\/s41581-021-00393-8","journal-title":"Nat Rev Nephrol"},{"key":"824_CR14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","volume":"30","author":"SJ Farber","year":"1951","unstructured":"Farber SJ et al (1951) Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30:125\u2013129","journal-title":"J Clin Invest"},{"key":"824_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E (2017) Sodium-Glucose Co-transporters and their inhibition: clinical physiology. Cell Metab 26:27\u201338. PMID: 28506519","journal-title":"Cell Metab"},{"key":"824_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1172\/JCI111133","volume":"72","author":"E Ferrannini","year":"1983","unstructured":"Ferrannini E et al (1983) Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737\u20131747. https:\/\/doi.org\/10.1172\/JCI111133","journal-title":"J Clin Invest"},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"Ferrannini","year":"2014","unstructured":"Ferrannini et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124:499\u2013508. https:\/\/doi.org\/10.1172\/JCI72227","journal-title":"J Clin Invest"},{"key":"824_CR18","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G et al (2015) Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:1730\u20131735. https:\/\/doi.org\/10.2337\/dc15-0355","journal-title":"Diabetes Care"},{"key":"824_CR19","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E et al (2016a) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190\u20131195. https:\/\/doi.org\/10.2337\/db15-1356","journal-title":"Diabetes"},{"key":"824_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E et al (2016b) CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis. Diabetes Care 39:1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"824_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E et al (2017) Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40:771\u2013776. https:\/\/doi.org\/10.2337\/dc16-2724","journal-title":"Diabetes Care"},{"key":"824_CR22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001178","volume":"8","author":"E Ferrannini","year":"2020","unstructured":"Ferrannini E et al (2020a) Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport. BMJ Open Diabetes Res Care 8:e001178","journal-title":"BMJ Open Diabetes Res Care"},{"key":"824_CR23","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2337\/dc20-0456","volume":"43","author":"E Ferrannini","year":"2020","unstructured":"Ferrannini E et al (2020b) Mechanisms of sodium-glucose cotransporter 2 inhibition: insights from large-scale proteomics. Diabetes Care 43:2183\u20132189. https:\/\/doi.org\/10.2337\/dc20-0456","journal-title":"Diabetes Care"},{"key":"824_CR24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db23-0448","volume":"73","author":"E Ferrannini","year":"2024","unstructured":"Ferrannini E et al (2024a) Role of glycosuria in SGLT2 inhibitor\u2013induced cardiorenal protection: a mechanistic analysis of the CREDENCE trial. Diabetes 73:250\u2013259","journal-title":"Diabetes"},{"key":"824_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.180637","volume":"9","author":"E Ferrannini","year":"2024","unstructured":"Ferrannini E et al (2024b) Fasting substrates predict chronic kidney disease progression in CREDENCEtrial patients with type 2 diabetes. JCI Insight 9:e180637. https:\/\/doi.org\/10.1172\/jci.insight.180637","journal-title":"JCI Insight"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2025.03.503","volume":"85","author":"JP Ferreira","year":"2025","unstructured":"Ferreira JP et al (2025) Effect of empagliflozin on the mechanisms driving erythropoiesis and iron mobilization in patients with heart failure: the EMPEROR program. J Am Coll Cardiol 85:1757\u20131770. https:\/\/doi.org\/10.1016\/j.jacc.2025.03.503","journal-title":"J Am Coll Cardiol"},{"key":"824_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V et al (2012) Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187\u2013196. https:\/\/doi.org\/10.2337\/db11-1029","journal-title":"Diabetes"},{"key":"824_CR28","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1053\/j.gastro.2017.01.052","volume":"152","author":"KD Hall","year":"2017","unstructured":"Hall KD, Guo J (2017) Obesity energetics: body weight regulation and the effects of diet composition. Gastroenterology 152:1718\u201327.e3. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.052","journal-title":"Gastroenterology"},{"key":"824_CR29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"AC Hesp","year":"2020","unstructured":"Hesp AC et al (2020) The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney Int 98:579\u2013589","journal-title":"Kidney Int"},{"key":"824_CR30","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","volume":"300","author":"CS Hummel","year":"2011","unstructured":"Hummel CS et al (2011) Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 300:C14\u2013C21. https:\/\/doi.org\/10.1152\/ajpcell.00388.2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"824_CR31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jdiacomp.2019.04.006","volume":"33","author":"D Kannenkeril","year":"2019","unstructured":"Kannenkeril D et al (2019) Tissue sodium content in patients with type 2 diabetes mellitus. J Diabetes Complicat 33:485\u2013489. https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.04.006","journal-title":"J Diabetes Complicat"},{"key":"824_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0654-z","volume":"17","author":"MV Karg","year":"2018","unstructured":"Karg MV et al (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol 17:5. https:\/\/doi.org\/10.1186\/s12933-017-0654-z","journal-title":"Cardiovasc Diabetol"},{"key":"824_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s41574-025-01170-4","volume":"21","author":"W-H Lee","year":"2025","unstructured":"Lee W-H et al (2025) Cardiometabolic and renal benefits of sodium-glucose cotransporter 2 inhibitors. Nat Rev Endocrinol 21:783\u2013798. https:\/\/doi.org\/10.1038\/s41574-025-01170-4","journal-title":"Nat Rev Endocrinol"},{"key":"824_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124:509\u2013514. https:\/\/doi.org\/10.1172\/JCI70704","journal-title":"J Clin Invest"},{"key":"824_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","volume":"28","author":"CE Mogensen","year":"1971","unstructured":"Mogensen CE (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28:101\u2013109","journal-title":"Scand J Clin Lab Invest"},{"issue":"6514","key":"824_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","volume":"370","author":"D Murashige","year":"2020","unstructured":"Murashige D et al (2020) Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science 370(6514):364\u2013368. https:\/\/doi.org\/10.1126\/science.abc8861","journal-title":"Science"},{"key":"824_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95107","volume":"3","author":"JM Nizar","year":"2018","unstructured":"Nizar JM et al (2018) Renal tubule insulin receptor modestly promotes elevated blood pressure and markedly stimulates glucose reabsorption. JCI Insight 3:e95107. https:\/\/doi.org\/10.1172\/jci.insight.95107","journal-title":"JCI Insight"},{"key":"824_CR38","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/dom.13003","volume":"19","author":"L Norton","year":"2017","unstructured":"Norton L et al (2017) Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 19:1322\u20131326. https:\/\/doi.org\/10.1111\/dom.13003","journal-title":"Diabetes Obes Metab"},{"key":"824_CR39","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/dom.14363","volume":"23","author":"J Oldgren","year":"2021","unstructured":"Oldgren J et al (2021) Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized, placebo-controlled, exploratory study. Diabetes Obes Metab 23:1505\u20131517. https:\/\/doi.org\/10.1111\/dom.14363","journal-title":"Diabetes Obes Metab"},{"key":"824_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","volume":"13","author":"M Packer","year":"2020","unstructured":"Packer M (2020a) Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors. Circ Heart Fail 13:e007197. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007197","journal-title":"Circ Heart Fail"},{"key":"824_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016270","volume":"9","author":"M Packer","year":"2020","unstructured":"Packer M (2020b) Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure. J Am Heart Assoc 9:e016270. https:\/\/doi.org\/10.1161\/JAHA.120.016270","journal-title":"J Am Heart Assoc"},{"key":"824_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M (2022) Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation 146:1383\u20131405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732","journal-title":"Circulation"},{"key":"824_CR43","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V et al (2019) CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"824_CR44","doi-asserted-by":"publisher","unstructured":"Polidoro ZJ et al (2025) Physical association of NHE3 and SGLT2 mediated by accessory proteins in the renal proximal tubule. Am J Physiol Renal Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00068.2025","DOI":"10.1152\/ajprenal.00068.2025"},{"key":"824_CR45","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc21-2166","volume":"45","author":"MG Posh","year":"2022","unstructured":"Posh MG et al (2022) Metabolic, intestinal, and cardiovascular effects of sotagliflozin compared with empagliflozin in patients with type 2 diabetes: a randomized, double-blind study. Diabetes Care 45:2118\u20132126. https:\/\/doi.org\/10.2337\/dc21-2166","journal-title":"Diabetes Care"},{"key":"824_CR46","first-page":"E1","volume":"268","author":"A Qui\u00f1ones Galvan","year":"1995","unstructured":"Qui\u00f1ones Galvan A et al (1995) Effect of insulin on uric acid excretion in humans. Am J Phys 268:E1\u2013E5","journal-title":"Am J Phys"},{"key":"824_CR47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(63)91500-9","volume":"1","author":"PJ Randle","year":"1963","unstructured":"Randle PJ et al (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785\u2013789","journal-title":"Lancet"},{"key":"824_CR48","doi-asserted-by":"crossref","first-page":"E871","DOI":"10.1152\/ajpendo.00135.2019","volume":"317","author":"E Rebelos","year":"2019","unstructured":"Rebelos E et al (2019) Renal hemodynamics and fatty acid uptake: effects of obesity and weight loss. Am J Physiol Endocrinol Metab 317:E871\u2013E878","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"824_CR49","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc15-1380","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Ferrannini E (2015) Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38:1638\u20131642. https:\/\/doi.org\/10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"824_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13051360","volume":"13","author":"P S\u00e1nchez-Briales","year":"2024","unstructured":"S\u00e1nchez-Briales P et al (2024) The uricosuric effect of SGLT2 inhibitors is maintained in the long term in patients with chronic kidney disease and type 2 diabetes mellitus. J Clin Med 13:1360. https:\/\/doi.org\/10.3390\/jcm13051360","journal-title":"J Clin Med"},{"key":"824_CR51","doi-asserted-by":"publisher","first-page":"24695","DOI":"10.1038\/s41598-024-76256-6","volume":"14","author":"H Sato","year":"2024","unstructured":"Sato H et al (2024) Model-based meta-analysis of HbA1c reduction across SGLT2 inhibitors using dose adjusted by urinary glucose excretion. Sci Rep 14:24695. https:\/\/doi.org\/10.1038\/s41598-024-76256-6","journal-title":"Sci Rep"},{"key":"824_CR52","doi-asserted-by":"publisher","unstructured":"Scholtes RA et al (2022) Kidney hemodynamic effects of angiotensin receptor blockade, sodium-glucose cotransporter-2 inhibition alone, and their combination: a crossover randomized trial in people with type 2 diabetes. Circulation 146. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061033","DOI":"10.1161\/CIRCULATIONAHA.122.061033"},{"key":"824_CR53","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.3892\/mmr.2019.10110","volume":"19","author":"L Shentang","year":"2019","unstructured":"Shentang L et al (2019) A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature. Mol Med Rep 19:4364\u20134376. https:\/\/doi.org\/10.3892\/mmr.2019.10110","journal-title":"Mol Med Rep"},{"key":"824_CR54","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/dom.12970","volume":"19","author":"A Solini","year":"2017","unstructured":"Solini A et al (2017) Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19:1289\u20131294. https:\/\/doi.org\/10.1111\/dom.12970","journal-title":"Diabetes Obes Metab"},{"key":"824_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112. https:\/\/doi.org\/10.1681\/ASN.2010030246","journal-title":"J Am Soc Nephrol"},{"key":"824_CR56","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ekir.2023.01.001","volume":"8","author":"MJB van Baar","year":"2023","unstructured":"van Baar MJB et al (2023) Acute effects of insulin infusion on kidney hemodynamic function in people with type 2 diabetes and Normal kidney function. Kidney Int Rep 8:916\u2013920. https:\/\/doi.org\/10.1016\/j.ekir.2023.01.001","journal-title":"Kidney Int Rep"},{"key":"824_CR57","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM et al (2020) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97:202\u2013212. https:\/\/doi.org\/10.1016\/j.kint.2019.09.013","journal-title":"Kidney Int"},{"key":"824_CR58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2337\/diacare.14.3.220","volume":"14","author":"P Weidmann","year":"1991","unstructured":"Weidmann P, Ferrari P (1991) Central role of sodium in hypertension in diabetic subjects. Diabetes Care 14:220\u2013232","journal-title":"Diabetes Care"},{"key":"824_CR59","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"9","author":"EM Wright","year":"2011","unstructured":"Wright EM et al (2011) Biology of human sodium glucose transporters. Physiol Rev 9:733\u2013794. https:\/\/doi.org\/10.1152\/physrev.00055.2009","journal-title":"Physiol Rev"},{"key":"824_CR60","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/dom.1385","volume":"21","author":"T Yakovleva","year":"2019","unstructured":"Yakovleva T et al (2019) Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: a quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diab Obes Metab 21:2684\u20132693. https:\/\/doi.org\/10.1111\/dom.1385","journal-title":"Diab Obes Metab"},{"key":"824_CR61","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B et al (2015) EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:53:13Z","timestamp":1789188793000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/164_2026_824","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"13 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}